Overview

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Objective: To investigate the efficacy, safety and tolerability of SI-B003 monotherapy and BL-B01D1+SI-B003 dual agents in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors, and to further explore the optimal dose and mode of combination.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.